Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

PHASE2TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

November 7, 2023

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions
CPVT1Heart Defects, CongenitalHeart DiseasesVentricular Tachycardia
Interventions
DRUG

CRD-4730

Oral CRD-4730 in capsule form

DRUG

Placebo

Placebo to match CRD-4730 in capsule form

Trial Locations (11)

27100

IRCCS Pavia Istituti Clinici Scientifici Maugeri Spa Società Benefit, Pavia

44195

Cleveland Clinic Children's Hospital, Cleveland

44805

Hôptal Nord Laennec, Nantes

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

69677

Hôpital Louis Pradel, Bron

75018

Groupe Hospitalier Bichat Claude Bernard, Paris

77030

Baylor College of Medicine, Houston

T6G 2R7

Stollery Children's Hospital University of Alberta, Edmonton

V5Z 1M9

University of British Columbia (UBC) Hospital, Vancouver

V6H 3N1

British Columbia Children's Hospital, Vancouver

N6A 5A5

University of Western Ontario, London

All Listed Sponsors
lead

Cardurion Pharmaceuticals, Inc.

INDUSTRY